Improved biodistribution of 125I-labeled anti-Tac disulfide- stabilized Fv fragment by blocking its binding to the α subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti- Tac IgG

Cancer Research

Volumn 57, Issue 10, 1997, Pages 1955-1961

  Kobayashi, Hisataka ^a   Yoo, Tae M ^a   Drumm, Debra ^a   Kim, Meyoung Kon ^a   Sun, Bao Fu ^a   Le, Nhat ^a   Webber, Keith O ^b   Pastan, Ira ^b   Waldmann, Thomas A ^b   Paik, Chang H ^a   Carrasquillo, Jorge A ^a,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; IODINE 125; MONOCLONAL ANTIBODY; DISULFIDE; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN G; IMMUNOTOXIN; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG DISTRIBUTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY; RECEPTOR BINDING; TISSUE DISTRIBUTION; TUMOR VOLUME; XENOGRAFT; ANIMAL; BLOOD; CANCER TRANSPLANTATION; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; IMMUNOLOGY; MACROMOLECULE; METABOLISM; NUDE MOUSE; ULTRASTRUCTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; DISULFIDES; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOTOXINS; IODINE RADIOISOTOPES; MACROMOLECULAR SUBSTANCES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RECEPTORS, INTERLEUKIN-2; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030611102     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Carrasquillo, J. A. Radioimmunotherapy of leukemia and lymphoma. In: H. Wagner (ed.) Principles of Nuclear Medicine, Ed. 2, pp. 1117-1132. Philadelphia: W. B. Saunders and Co., 1996.
2. Larson, S. M., Divgi, C. R., and Scott, A. M. Overview of clinical radioimmunodetection of human tumors. Cancer (Phila.), 73: 832-835, 1994.
3. Pimm, M. V. Circulating antigen: bad or good for immunoscintigraphy? Nucl. Med. Biol., 22: 137-145, 1995.
4. Douillard, J. Y., Chatal, J. F., Saccavini, J. C., Curtet, C., Kremer, M., Peuvrel, P., and Koprowski, H. Pharmacokinetic study of radiolabeled anti-colorectal carcinoma monoclonal antibodies in tumor-bearing nude mice. Eur. J. Nucl. Med., 11: 107-113, 1985.
5. 111In-labelled F(ab′)2 fragments of human prostatic acid phosphatase monoclonal antibody in nude mice bearing PC-82 human prostatic tumour xenografts. Eur. J. Nucl. Med., 18: 339-345, 1991.
6. Watanabe, Y., Endo, K., Koizumi, M., Kawamura, Y., Saga, T., Sakahara, H., Kuroki, M., Matsuoka, Y., and Konishi, J. Effect of tumor mass and antigenic nature on the biodistribution of labeled monoclonal antibodies in mice. Cancer Res., 49: 2884-2889, 1989.
7. Pimm, M. V., Durrant, L. G., and Baldwin, R. W. Influence of circulating antigen on the biodistribution and tumour localization of radiolabelled monoclonal antibody in a human tumour: nude mouse xenograft model. Eur. J. Cancer Clin. Oncol., 25: 1325-1332, 1989.
8. Kobayashi, H., Sakahara, H., Saga, T., Hosono, M., Shirato, M., Kanda, H., Ishibashi, K., Watanabe, T., Endo, K., Ishiwata, I., and Konishi, J. A human/mouse chimeric monoclonal antibody against CA125 for radioimmunoimaging of ovarian cancer. Cancer Immunol. Immunother., 37: 143-149, 1993.
9. Hagan, P. L., Halpern, S. E., Chen, A., Krishnan, L., Frincke, J., Bartholomew, R. M., David, G. S., and Carlo, D. In vivo kinetics of radiolabeled monoclonal anti-CEA antibodies in animal models. J. Nucl. Med., 26: 1418-1423, 1985.
10. 111In-labeled anticarcinoembryonic antigen monoclonal antibody in nude mice bearing human colon cancer xenografts. Cancer Res., 49: 1587-1594, 1989.
11. Duewell, S., Horst, W., and Westera, G. Uptake of a monoclonal antibody against CEA (Tumak 431/31) in a human colon tumor (Co-112) xenografted in the nude mouse. Dependence on tumor size and injected dose. Cancer Immunol. Immunother., 23: 101-106, 1986.
12. Carrasquillo, J. A., Sugarbaker, P., Colcher, D., Reynolds, J. C., Esteban, J., Bryant, G., Keenan, A. M., Perentesis, P., Yokoyama, K., Simpson, D. E., Ferroni, P., Farkas, R., Schlom, J., and Larson, S. M. Radioimmunoscintigraphy of colon cancer with iodine-131-labeled B72.3 monoclonal antibody. J. Nucl. Med., 29: 1022-1030, 1988.
13. Colcher, D., Esteban, J. M., Carrasquillo, J. A., Sugarbaker, P., Reynolds, J. C., Bryant, G., Larson, S. M., and Schlom, J. Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. Cancer Res., 47: 1185-1189, 1987.
14. Colcher, D., Milenic, D. E., Ferroni, P., Carrasquillo, J. A., Reynolds, J. C., Roselli, M., Larson, S. M., and Schlom, J. In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J. Nucl. Med., 31: 1133-1142, 1990.
15. Yu, B., Carrasquillo, J., Milenic, D., Chung, Y., Perentesis, P., Feuerestein, I., Eggensperger, D., Qi, C. F., Paik, C., Reynolds, J., Grem, J., Curt, G., Siler, K., Schlom, J., and Allegra, C. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J. Clin. Oncol., 14: 1798-1809, 1996.
16. Behr, T. M., Sharkey, R. M., Juweid, M. I., Dunn, R. M., Ying, Z., Zhang, C. H., Siegel, J. A., Gold, D. V., and Goldenberg, D. M. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors. Cancer Res., 56: 1805-1816, 1996.
17. Davis, Q., Perkins, A. C., Symonds, E. M., Frier, M., Wastie, M. L., van Hof, A. C., Ross, J. C., den Hollander, W., Sopwith, M., and Kenemans, P. Immunoscintigraphy of ovarian cancer using a CDR grafted antibody (hCTM01): first clinical results. Nuklearmedizin, 33: 62, 1994.
18. 111indium-labelled monoclonal antibody CTM01 (hCTM01) in ovarian cancer patients. Nuklearmedizin, 33: 60, 1994.
19. Kay, N. E., Burton, J., Wagner, D., and Nelson, D. L. The malignant B cell from B-chronic lymphocytic leukemia patients release Tac-soluble interleukin-2 receptors. Blood, 72: 447-450, 1988.
20. Richards, J., Mick, R., Latta, J. M., Daly, K., Ratain, M. J., Vardiman, J. W., and Colomb, H. M. Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood, 76: 1941-1945, 1990.
21. Motoi, T., Uchiyama, T., Hori, T., Itoh, K., Uchino, H., and Ueda, R. Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis. Blood, 74: 1052-1057, 1989.
22. Ambrosetti, A., Semenzato, G., Prior, M., Chilosi, M., Vinante, F., Vincenzi, C., Zanotti, R., Trentin, L., Portuese, A., Menestrina, F., Perona, G., Agostini, C., and Todeschini, G. Serum levels of soluble interleukin-2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulk. Br. J. Haematol., 73: 181-186, 1989.
23. Wolf, R. E., and Brelsford, W. G. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum., 31: 729-735, 1988.
24. Nakanishi, K., Taniguchi, Y., and Ohta, Y. Increased soluble interleukin 2 receptor levels in autoimmune thyroid disease. Acta Endocrinol. (Copenh)., 125: 253-258, 1991.
25. Anasetti, C., Hansen, J. A., Waldmann, T. A., Appelbaum, F. R., Davis, J., Deeg, H. J., Doney, K., Martin, P. J., Nash, R., Storb, R., Sullivan, K. M., Witherspoon, R. P., Binger, M-H., Chizzonite, R., Hakimi, J., Mould, D., Satoh, H., and Light, S. E. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood, 84: 1320-1327, 1994.
26. Waldmann, T. A., Kozak, R. W., Tsudo, M., Oh-ishi, T., Bongiovanni, K. F., and Goldman, C. K. IL-2 receptors in adult T-cell leukemia: a target for immunotherapy. Hamatol. Bluttransfus, 31: 110-115, 1987.
27. Uchiyama, T., Broder, S., and Waldmann, T. A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J. Immunol., 126: 1393-1397, 1981.
28. Waldmann, T. A., White, J. D., Carrasquillo, J. A., Reynolds, J. C., Paik, C. H., Gansow, O. A., Brechbiel, M. W., Jaffe, E. S., Fleisher, T. A., Goldman, C. K., Top, L. E., Bamford, R., Zaknoen, S., Roessler, E., Kasten-Sportes, C., England, R., Litou, H., Johnson, J. A., Jackson-White, T., Manns, A., Hanchard, B., Junghans, R. P., and Nelson, D. L. Radioimmunotherapy of interleukin-2R α-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood, 86: 4063-4075, 1995.
29. Cooper, M. M., Robbins, R. C., Goldman, C. K., Mirzadeh, S., Brechbiel, M. W., Stone, C. D., Gansow, O. A., Clark, R. E., and Waldmann, T. A. Use of yttrium-90-labeled anti-Tac antibody in primate xenograft transplantation. Transplantation, 50: 760-765, 1990.
30. Parenteau, G. L., Dirbas, F. M., Garmestani, K., Brechbiel, M. W., Bukowski, M. A., Goldman, C. K., Clark, R., Gansow, O. A., and Waldmann, T. A. Prolongation of graft survival in primate allograft transplantation by yttrium-90-labeled anti-Tac in conjunction with granulocyte colony-stimulating factor. Transplantation, 54: 963-968, 1992.
31. Yokota, T., Milenic, D. E., Whitlow, M., and Schlom, J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res., 52: 3402-3408, 1992.
32. Yokota, T., Milenic, D. E., Whitlow, M., Wood, J. F., Hubert, S. L., and Schlom, J. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res., 53: 3776-3783, 1993.
33. Reynolds, J. C., Del Vecchio, S., Sakahara, H., Lora, M. E., Carrasquillo, J. A., Neumann, R. D., and Larson, S. M. Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications. Int. J. Radiat. Appl. Instrum. Part B, 16: 121-125, 1989.
34. Webber, K. O., Kreitman, R. J., and Pastan, I. Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors. Cancer Res., 55: 318-323, 1995.
35. 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 α receptor-positive tumor xenografts. Cancer Res., 55: 5323-5329, 1995.
36. 99mTc-labeled anti-Tac dsFv. Cancer Res., 56: 3788-3795, 1996.
37. Yoo, T. M., Chang, H. K., Choi, C. W., Webber, K. O., Le, N., Sood, V. K., Carrasquillo, J. A., Eckelman, W. C., Pastan, I., and Paik, C. H. Radiolabeling of anti-Tac disulfide stabilized Fv fragment with Tc-99m and its evaluation in athymic mice with tumor xenografts. J. Nucl. Med., 38: 294-300, 1997.
38. Huston, J. S., Mudgett-Hunter, M., Tai, M. S., McCartney, J., Warren, F., Haber, E., and Oppermann, H. Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol., 203: 46-88, 1991.
39. Schlom, J., Milenic, D. E., Roselli, M., Colcher, D., Bird, R., Johnson, S., Hardman, K. D., Guadagni, F., and Greiner, J. W. New concepts in monoclonal antibody based radioimmunodiagnosis and radioimmunotherapy of carcinoma. Int. J. Radiat. Appl. Instrum. Part B, 18: 425-435, 1991.
40. Reiter, Y., Brinkmann, U., Kreitman, R. J., Jung, S. H., Lee, B., and Pastan, I. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry, 33: 5451-5459, 1994.
41. Brinkmann, U., Chowdhury, P. S., Roscoe, D. M., and Pastan, I. Phage display of disulfide-stabilized Fv fragments. J. Immunol. Methods, 182: 41-50, 1995.
42. Colcher, D., Bird, R., Roselli, M., Hardman, K. D., Johnson, S., Pope, S., Dodd, S. W., Pantoliano, M. W., Milenic, D. E., and Schlom, J. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J. Natl. Cancer Inst., 82: 1191-1197, 1990.
43. Milenic, D. E., Yokota, T., Filpula, D. R., Finkelman, M. A., Dodd, S. W., Wood, J. F., Whitlow, M., Snoy, P., and Schlom, J. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res., 51: 6363-6371, 1991.
44. Schott, M. E., Milenic, D. E., Yokota, T., Whitlow, M., Wood, J. F., Fordyce, W. A., Cheng, R. C., and Schlom, J. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules. Cancer Res., 52: 6413-6417, 1992.
45. Chester, K. A., Begent, R. H., Robson, L., Keep, P., Pedley, R. B., Boden, J. A., Boxer, G., Green, A., Winter, G., Cochet, O., and Hawkins, R. E. Phage libraries for generation of clinically useful antibodies. Lancet, 343: 455-456, 1994.
46. Tai, M. S., McCartney, J. E., Adams, G. P., Jin, D., Hudziak, R. M., Oppermann, H., Laminet, A. A., Bookman, M. A., Wolf, E. J., Liu, S., Stafford, W. F., III, Fand, I., Houston, L. L., Weiner, L. M., and Huston, J. S. Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers. Cancer Res., 55: 5983s-5989s, 1995.
47. Webber, K. O., Reiter, Y., Brinkmann, U., Kreitman, R., and Pastan, I. Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. Mol. Immunol., 32: 249-258, 1995.
48. Uchiyama, T., Nelson, D. L., Fleisher, T. A., and Waldmann, T. A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells. J. Immunol., 126: 1398-1403, 1981.
49. Queen, C., Schneider, W. P., Selick, H. E., Payne, P. W., Landolfi, N. F., Duncan, J. F., Avdalovic, N. M., Levitt, M., Junghans, R. P., and Waldmann, T. A. A humanized antibody that hinds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA, 86: 10029-10033, 1989.
50. Fruker, P. J., and Speck, J. C., Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide. 1,3,4,6-tetrachloro-3α,6α-diphrenylglycoluril. Biochem. Biophys. Res. Commun., 80: 849-857, 1978.
51. 131I-labelled human growth hormone of high specific radioactivity. Biochem. J., 89: 114-123, 1963.
52. Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J., and Bunn, P. A., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods, 72: 77-89, 1984.
53. 212Bi-anti-Tac. Cancer Res., 54: 4362-4370, 1994.
54. 111In from labelled monoclonal antibody fragments. Nucl. Med. Commun., 16: 710-711, 1995.
55. Behr, T. M., Sharkey, R. M., Juweid, M. E., Blumenthal, R. D., Dunn, R. M., Griffiths, G. L., Bair, H. J., Wolf, F. G., Becker, W. S., and Goldenberg, D. M. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res., 55: 3825-3834, 1995.
56. Waldmann, T. A., Goldman, C. K., Bongiovanni, K. F., Sharrow, S. O., Davey, M. P., Cease, K. B., Greenberg, S. J., and Longo, D. L. Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood, 72: 1805-1816, 1988.
57. Larson, S. M., Brown, J. P., Wright, P. W., Carrasquillo, J. A., Hellstrom, I., and Hellstrom, K. E. Imaging of melanoma with I-131-labeled monoclonal antibodies. J. Nucl. Med., 24: 123-129, 1983.
58. 123I-labeled Fab or F(ab′)2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J. Clin. Invest., 77: 301-311, 1986.
59. Junghans, R. P., and Waldmann, T. A. Metabolism of Tac (IL2Rα): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J. Exp. Med., 183: 1587-1602, 1996.
60. Berson, S. A., and Yalow, R. S. Insulin in blood and insulin antibodies. Am. J. Med., 40: 676-690, 1966.
61. Hakimi, J., Chizzonite, R., Luke, D. R., Familletti, P. C., Bailon, P., Kondas, J. A., Pilson, R. S., Lin, P., Weber, D. V., Spence, C., Mondini, L. J., Tsien, W-H., Levin, J. L., Gallati, V. H., Korn, L., Waldmann, T. A., Queen, C., and Benjamin, W. R. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J. Immunol., 147: 1352-1359, 1991.